Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
Status:
Completed
Trial end date:
2018-11-12
Target enrollment:
Participant gender:
Summary
Essential hypertension (HTN) is a disease that affects approximately 1 billion individuals
worldwide. Despite the availability of effective and safe anti-hypertensive drugs, 65% of
subjects diagnosed with HTN do not have their blood pressure (BP) controlled (<140/90 mmHg).
The overall incidence of resistant HTN, (defined as requiring 3 or more anti-hypertensive
drugs, including a diuretic, to control BP) is estimated to be 15% of the hypertensive
population. Consequently, there is a pressing unmet medical need to develop new classes of
anti-hypertensive drugs that act on alternative pathways and further control BP and the
associated cardiovascular risks in subjects.
The prevalence of HTN in African Americans in the United States is among the highest in the
world, and HTN is more common in African Americans than in Caucasians. One of the risk
factors for HTN is sodium sensitivity. There is a higher association of HTN with sodium
sensitivity in African American subjects and other racial/ethnic groups who are
overweight/obese.
Effective agents to treat HTN in this high-risk population are clearly needed.
This study will be conducted in a hypertensive, overweight subject population of multiple
ethnic origins in which QGC001 is likely, based on its mode of action, to demonstrate a
significant anti-hypertensive effect.